Thermo Fisher Scientific launched its Ion Torrent Genexus System, a fully-integrated next-generation sequencing platform featuring an automated specimen-to-report workflow that, according to the company, is able to deliver results one day.
African Americans and Hispanic people with multiple myeloma start treatment with a novel therapy significantly later than white patients, according to a study published Oct. 17 in Blood Advances.
Many non-white minority cancer survivors place importance on seeing doctors who share or understand their culture, but are less likely than non-Hispanic whites to be able to see such physicians, according to a new study from Dana-Farber Cancer Institute and University of Texas Southwestern.
The National Comprehensive Cancer Network published guidelines that provide step-by-step information on best practices in evaluating patients for hematopoietic cell transplantation and managing complications afterwards.
St. Jude Children's Research Hospital's Total Therapy Study 16 showed a reduced rate of central nervous system relapse in acute lymphoblastic leukemia, according to results published online Oct. 28 in the Journal of Clinical Oncology.
The phase III IMbrave150 study evaluating Tecentriq in combination with Avastin in people with unresectable hepatocellular carcinoma met its co-primary endpoints of overall survival and progression-free survival, compared with standard-of-care sorafenib.
Wide Field Optical Coherence Tomography has the potential to significantly reduce the need for additional surgery after breast tumor resection, according to a study published in The Breast Journal.
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute report a discovery that helps scientists understand why some tumors lack immune cell infiltration and are therefore unresponsive to newer PD-1 targeted therapies.
Researchers have found an antibody, imatinib, that eliminates chronic myeloid leukemia stem cells in mice and isolated human cancer cells and could keep one form of the disease from persisting after treatment.
A phase 3 clinical trial, CheckMate-9LA, evaluating Bristol-Myers Squibb's Opdivo (nivolumab) + low-dose Yervoy (ipilimumab), together with two cycles of chemo, for the first-line treatment of advanced non-small cell lung cancer met the primary endpoint of overall survival compared to chemo alone for up to four cycles followed by optional maintenance therapy.
